Skip to content

Clinical trials

Phase 4 Diabetes Mellitus, Type 2 trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Phase 4 Country / region: China Clear all

147 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20023
20031
20043
20053
20062
20073
20086
20098
20105
20119
20128
201310
20149
201512
20166
20177
20185
20196
20204
20215
20227
20234
20249
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed89
Unknown status33
Recruiting14
Not yet recruiting7
Terminated3
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S20
Sanofi11
Shanghai Jiao Tong University School of Medicine9
Sun Yat-sen University7
Eli Lilly and Company6
AstraZeneca5
Shanghai Zhongshan Hospital5
Xiang Guang-da4
Huazhong University of Science and Technology3
Nanjing First Hospital, Nanjing Medical University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 2147
Diabetes Mellitus29
Coronary Artery Disease6
Albuminuria4
Insulin Resistance4
Metabolic Diseases4
Non-alcoholic Fatty Liver Disease4
Obesity4
Diabetes Mellitus, Type 13
Glucose Metabolism Disorders3

Trials

Showing 1 to 25 of 147. Each trial links to its page on Pharma Observatory.

47 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.